Stay updated with breaking news from Danielj Oconnor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
B. Riley downgraded shares of Ambrx Biopharma (NYSE:AMAM – Free Report) from a buy rating to a neutral rating in a research report report published on Tuesday, Marketbeat Ratings reports. B. Riley currently has $28.00 price objective on the stock, up from their previous price objective of $26.00. Several other brokerages have also recently commented […]
Johnson & Johnson agreed to acquire Ambrx Biopharma, which is developing cancer treatments. The biotech was spun out from The Scripps Research Institute in 2003.
PALM BEACH, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to the report titled
PALM BEACH, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to the report titled 'Aging in the United States,...
08.01.2024 - SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) - Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), today announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of the outstanding shares of Ambrx for ... Seite 1